FINWIRES · TerminalLIVE
FINWIRES

Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration

By

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) said its Xinxin Pharmaceutical Plant has a drug registration certificate from China's National Medical Products Administration for a drug used to help control blood sugar in adults with type 2 diabetes.

The drug is Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (I), according to a Friday filing with the Singapore Exchange.

Da Ren Tang said the approval is not expected to have a material impact on its short-term financial performance.

Production and sales will remain subject to regulatory requirements, market conditions and national policies, the company said.

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245